Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Michael O’Dwyer

Academic History

Michael O’Dwyer is a Clinician Scientist who specializes in hematologic oncology. Prof. O’Dwyer established and is the director of the Blood Cancer Network, Ireland (BCNI), and leads the development of Phase I trial capability in Ireland. Prof. O’Dwyer contributed to the clinical development of Imatinib, the first effective molecular targeted therapy.

Speaking on cellular therapies for multiple myeloma

Prof. O’Dwyer focuses on understanding translational glycobiology in cancer, reversing immune tolerance/suppression in the tumour microenvironment and the use and modification of natural killer (NK) cells as cell therapy for cancer. Prof. O’Dwyer specializes in multiple myeloma, lymphoma and chronic lymphocytic leukemia.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.